{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"88","value":"468.440"},{"groupId":"OG001","spread":"95","value":"308.144"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"C1D15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"110","value":"462.806"},{"groupId":"OG001","spread":"52","value":"167.483"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"C2D1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Trough plasma concentration was defined as the estimated lowest concentration before next dose administration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG000","title":"AML Cohort"},{"description":"Participants received SC or IV administration of azacitidine at the starting dose of 75 mg/m2/day for 7 days every 28 days, and received oral self-administration of glasdegib daily and continuously at home with a starting dose of 100 mg QD.","id":"OG001","title":"MDS Cohort"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK concentration analysis set included all participants who received treatment and had at least 1 value of analyte concentration of glasdegib or azacitidine available. Number of participants analyzed = number of participants evaluable for this OM. Number analyzed = number of participants with evaluable results at the specific timepoint.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1 and 4 hours post-dose on Cycle 1 Day 15 (C1D15) and Cycle 2 Day 1 (C2D1)","title":"Trough Plasma Concentration (Ctrough) of Glasdegib on Cycle 1 Day 15 and Cycle 2 Day 1 in the AML and MDS Cohorts","type":"SECONDARY","unitOfMeasure":"ng/mL"}